Literature DB >> 19273109

Ectoenzymes and innate immunity: the role of human CD157 in leukocyte trafficking.

Ada Funaro1, Erika Ortolan, Paola Bovino, Nicola Lo Buono, Giulia Nacci, Rossella Parrotta, Enza Ferrero, Fabio Malavasi.   

Abstract

CD157 is a glycosylphosphatidylinositol-anchored molecule encoded by a member of the CD38/ADP-ribosyl cyclase gene family, involved in the metabolism of NAD. Expressed mainly by cells of the myeloid lineage and by vascular endothelial cells, CD157 has a dual nature behaving both as an ectoenzyme and as a receptor. Although it lacks a cytoplasmic domain, and cannot transduce signals on its own, the molecule compensates for this structural limit by interacting with conventional receptors. Recent experimental evidence suggests that CD157 orchestrates critical functions of human neutrophils. Indeed, CD157-mediated signals promote cell polarization, regulate chemotaxis induced through the high affinity fMLP receptor and control transendothelial migration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273109     DOI: 10.2741/3287

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  14 in total

1.  Binding of CD157 protein to fibronectin regulates cell adhesion and spreading.

Authors:  Simona Morone; Stefania Augeri; Massimiliano Cuccioloni; Matteo Mozzicafreddo; Mauro Angeletti; Nicola Lo Buono; Alice Giacomino; Erika Ortolan; Ada Funaro
Journal:  J Biol Chem       Date:  2014-04-21       Impact factor: 5.157

Review 2.  Ectoenzymes in leukocyte migration and their therapeutic potential.

Authors:  Marko Salmi; Sirpa Jalkanen
Journal:  Semin Immunopathol       Date:  2014-03-18       Impact factor: 9.623

Review 3.  Electroosmotic perfusion of tissue: sampling the extracellular space and quantitative assessment of membrane-bound enzyme activity in organotypic hippocampal slice cultures.

Authors:  Yangguang Ou; Juanfang Wu; Mats Sandberg; Stephen G Weber
Journal:  Anal Bioanal Chem       Date:  2014-08-29       Impact factor: 4.142

4.  Novel SCRG1/BST1 axis regulates self-renewal, migration, and osteogenic differentiation potential in mesenchymal stem cells.

Authors:  Emiko Aomatsu; Noriko Takahashi; Shunsuke Sawada; Naoto Okubo; Tomokazu Hasegawa; Masayuki Taira; Hiroyuki Miura; Akira Ishisaki; Naoyuki Chosa
Journal:  Sci Rep       Date:  2014-01-13       Impact factor: 4.379

5.  Human canonical CD157/Bst1 is an alternatively spliced isoform masking a previously unidentified primate-specific exon included in a novel transcript.

Authors:  Enza Ferrero; Nicola Lo Buono; Simona Morone; Rossella Parrotta; Cecilia Mancini; Alfredo Brusco; Alice Giacomino; Stefania Augeri; Antonio Rosal-Vela; Sonia García-Rodríguez; Mercedes Zubiaur; Jaime Sancho; Alessandra Fiorio Pla; Ada Funaro
Journal:  Sci Rep       Date:  2017-11-21       Impact factor: 4.379

Review 6.  Two novel mechanisms for maintenance of stemness in mesenchymal stem cells: SCRG1/BST1 axis and cell-cell adhesion through N-cadherin.

Authors:  Naoyuki Chosa; Akira Ishisaki
Journal:  Jpn Dent Sci Rev       Date:  2017-11-09

7.  SCRG1 suppresses LPS-induced CCL22 production through ERK1/2 activation in mouse macrophage Raw264.7 cells.

Authors:  Manabu Inoue; Junko Yamada; Emiko Aomatsu-Kikuchi; Kazuro Satoh; Hisatomo Kondo; Akira Ishisaki; Naoyuki Chosa
Journal:  Mol Med Rep       Date:  2017-04-20       Impact factor: 2.952

8.  Soluble CD157 in pleural effusions: a complementary tool for the diagnosis of malignant mesothelioma.

Authors:  Stefania Augeri; Stefania Capano; Simona Morone; Giulia Fissolo; Alice Giacomino; Silvia Peola; Zahida Drace; Ida Rapa; Silvia Novello; Marco Volante; Luisella Righi; Enza Ferrero; Erika Ortolan; Ada Funaro
Journal:  Oncotarget       Date:  2018-04-27

9.  Overexpression of CD157 contributes to epithelial ovarian cancer progression by promoting mesenchymal differentiation.

Authors:  Simona Morone; Nicola Lo-Buono; Rossella Parrotta; Alice Giacomino; Giulia Nacci; Alfredo Brusco; Alexey Larionov; Paola Ostano; Maurizia Mello-Grand; Giovanna Chiorino; Erika Ortolan; Ada Funaro
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

Review 10.  Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.

Authors:  Christian M Schürch
Journal:  Front Oncol       Date:  2018-05-18       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.